Recent Quotes

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-09-04
REV		(EXPECTED)2021-09-04

Q1 2021		Est.		Actual		Surprise
EPS				-0.620
REV				286.000K

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
FHTX	Foghorn Therapeutics	10.24	0.00	0%		377.3M

Foghorn Therapeutics Frequently Asked Questions

How do I buy Foghorn Therapeutics (FHTX) stock?

You can purchase shares of Foghorn Therapeutics (NASDAQ: FHTX) through any online brokerage.

View our list of the best stock brokerages.

Who are Foghorn Therapeutics's (FHTX) competitors?

Other companies in Foghorn Therapeutics’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Outlook Therapeutics (NASDAQ:OTLK), Fortress Biotech (NASDAQ:FBIO), 89bio (NASDAQ:ETNB) and Jounce Therapeutics (NASDAQ:JNCE).

What is the target price for Foghorn Therapeutics (FHTX) stock?

The latest price target for Foghorn Therapeutics (NASDAQ: FHTX) was reported by Morgan Stanley on March 23, 2021. The analyst firm set a price target for 23.00 expecting FHTX to rise to within 12 months (a possible 124.61% upside). 5 analyst firms have reported ratings in the last year.

Current Stock Price for Foghorn Therapeutics (FHTX)?

The stock price for Foghorn Therapeutics (NASDAQ: FHTX) is $10.24 last updated Wed Jun 23 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Does Foghorn Therapeutics (FHTX) pay a dividend?

There are no upcoming dividends for Foghorn Therapeutics.

When is Foghorn Therapeutics (NASDAQ:FHTX) reporting earnings?

Foghorn Therapeutics’s Q2 earnings are confirmed for after-market on September 4, 2021.

Is Foghorn Therapeutics (FHTX) going to split?

There is no upcoming split for Foghorn Therapeutics.

What sector and industry does Foghorn Therapeutics (FHTX) operate in?

Foghorn Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.